<DOC>
	<DOCNO>NCT02175602</DOCNO>
	<brief_summary>The purpose study assess effect Daclatasvir , Asunaprevir , BMS-791325 pharmacokinetics selective serotonin reuptake inhibitor .</brief_summary>
	<brief_title>Study Drug Combination Pharmacokinetics Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>1 . Signed Informed Consent Form ) Signed write informed consent must obtain subject accordance requirement study center 's IRB IEC initiation protocolrequired procedure . 2 . Target Population ) Healthy subject determine clinically significant deviation normal medical history , psychiatric history , physical examination finding , vital sign measurement , 12lead ECG measurement , physical measurement , clinical laboratory test result . 3 . Age Reproductive Status 1 . Males female , age 25 55 year , inclusive . 2 . Women childbearing potential ( WOCBP ) must negative serum pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 24 hour prior start study drug . 3 . Women must breastfeed . 1 . Any significant acute chronic medical illness . 2 . Current recent ( within 3 month study drug administration ) gastrointestinal disease could impact upon absorption study drug ( appendectomy complication allow investigator 's discretion ) . 3 . Any major surgery within 4 week study drug administration . 4 . Smokers ( currently smoke , well stop smoke less 6 month prior start study drug administration ) . 5 . Any sound medical , psychiatric , and/or social reason determine investigator .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>